The clinical progression of CRPC is currently determined by the following three factors: serum testosterone reaching desmoplastic levels (i.e., <50 ng/dL or <1.7 nmol/L), persistent elevation of prostate-specific antigen (PSA) and tumor progression visible in images [9]. Here, KLK3 is linked to neoplasm.